Biocomputational Prioritization of Cucurbitacins as Candidate Inhibitors of Human Pancreatic Lipase
Pharmacognosy Magazine · 12.10.2026
DOI: 10.1177/09731296261488113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacognosy Magazine, online erschienen am 12.10.2026. Verfasst von Nawaf Alshammari und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim/Background Obesity is a multifactorial metabolic disorder associated with substantial morbidity and mortality. Human pancreatic lipase is a validated therapeutic target because its inhibition can reduce the digestion and intestinal absorption of dietary triglycerides. This study aimed to computationally evaluate cucurbitacins as candidate pancreatic lipase inhibitors. Materials and Methods A library of 71 cucurbitacins was screened against human pancreatic lipase using AutoDock Vina. Orlistat, a clinically approved pancreatic lipase inhibitor, was included as the positive-control compound. The three highest-ranked cucurbitacins and orlistat were subjected to 100-ns molecular dynamics simulations using GROMACS 2022. Physicochemical, pharmacokinetic, and toxicity properties of the selected cucurbitacins were predicted using the absorption, distribution, metabolism, excretion, and toxicity–artificial intelligence (ADMET-AI) platform.
Results
Cucurbitacins F, H, and K produced docking scores of −8.8, −8.7, and −8.4 kcal/mol, respectively, compared with −6.7 kcal/mol for orlistat. The selected compounds occupied the pancreatic lipase catalytic pocket and maintained persistent protein-ligand interactions during the 100-ns simulations. Cucurbitacin K showed the lowest mean protein-backbone root mean square deviation (RMSD), whereas cucurbitacin F showed the lowest ligand RMSD and the highest average number of hydrogen bonds. Numerical ADMET predictions supported further prioritization of the compounds while identifying physicochemical and metabolic properties requiring experimental evaluation.
Conclusion
Cucurbitacins F, H, and K were computationally prioritized as candidate binders of human pancreatic lipase. These findings provide a basis for subsequent binding free-energy calculations, pancreatic lipase inhibition assays, and in vivo validation, but do not establish confirmed inhibitory or anti-obesity efficacy.
Zitieren
APA
Alshammari, N., Saeed, M., Al-Keridis, L. A., Siddiqui, S., Khan, N., & Alharbi, A. M. (2026). Biocomputational Prioritization of Cucurbitacins as Candidate Inhibitors of Human Pancreatic Lipase. Pharmacognosy Magazine. https://doi.org/10.1177/09731296261488113
Vancouver
Alshammari N, Saeed M, Al-Keridis LA, Siddiqui S, Khan N, Alharbi AM. Biocomputational Prioritization of Cucurbitacins as Candidate Inhibitors of Human Pancreatic Lipase. Pharmacognosy Magazine. 2026. doi:10.1177/09731296261488113
BibTeX
@article{Alshammari2026,
author = {Alshammari, Nawaf and Saeed, Mohd and Al-Keridis, Lamya Ahmed and Siddiqui, Samra and Khan, Nida and Alharbi, Ahmed M.},
title = {Biocomputational Prioritization of Cucurbitacins as Candidate Inhibitors of Human Pancreatic Lipase},
journal = {Pharmacognosy Magazine},
year = {2026},
doi = {10.1177/09731296261488113}
}
EUVIMED